NCT07305844 is a EARLY_PHASE1 clinical trial of LC106 in Bacterial Vaginosis, sponsored by Caroline Mitchell.

Who is sponsoring NCT07305844?

NCT07305844 is sponsored by Caroline Mitchell.

What drugs are being tested in NCT07305844?

Interventions in NCT07305844: LC106.

What condition does NCT07305844 study?

NCT07305844 studies Bacterial Vaginosis.

Is NCT07305844 still recruiting?

NCT07305844 is currently not yet recruiting. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT07305844

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Clinician-administered Vaginal Live Biotherapeutic Product

Not yet recruiting EARLY_PHASE1 Last updated 15 April 2026

What this trial tests

EARLY_PHASE1 trial testing LC106 in Bacterial Vaginosis in 71 participants. Not yet recruiting.

Timeline

22 April 2026

Primary endpoint
30 May 2026

30 May 2026

Quick facts

Lead sponsor	Caroline Mitchell
Phase	EARLY_PHASE1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	71
Start date	22 April 2026
Primary completion	30 May 2026
Estimated completion	30 May 2026
Sites	2 locations across South Africa, United States

Drugs / interventions tested

LC106 — full drug profile →

Conditions studied

Bacterial Vaginosis — all drugs for Bacterial Vaginosis →

Sponsor

Caroline Mitchell — full company profile →

Who can join

Adults 18 to 40, female only, with Bacterial Vaginosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, single-arm, Phase Ib trial assessing the consistency of response and colonization kinetics of a vaginally inserted live biotherapeutic intervention with optimized adherence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of LC106

Trials testing the same drug.

NCT06135974 — Vaginal lIve Biotherapeutic RANdomized Trial · EARLY_PHASE1 · completed

Other recruiting trials for Bacterial Vaginosis

Currently open trials in the same condition.

NCT07234786 — Clinical Study of a Vaginal Gel for the Treatment and Prevention of Vaginal Infections · NA · recruiting
NCT06458543 — Optimization of Bacterial Vaginosis Treatment in Women of Reproductive Age · Phase 4 · recruiting
NCT06263465 — Precision Vaginal Microbiome Transplantation in Women With Bacterial Vaginosis · NA · recruiting
NCT05753813 — Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome · EARLY_PHASE1 · recruiting
NCT06616168 — Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07305844 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Caroline Mitchell
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07305844.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing